Apyx Medical Corporation (APYX)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX). Investors who purchased Apyx securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Apyx and certain of its officers and/or directors have violated federal securities laws.


On March 14, 2022, Apyx issued a press release “announc[ing] it has been notified by the U.S. Food and Drug Administration (‘FDA’; ‘Agency’) that the Agency intends to post a Medical Device Safety Communication related to the Company’s Advanced Energy products.”  In the press release, Apxy’s President and Chief Executive Officer stated that “[b]ased on our initial interactions with the FDA, we believe the Agency’s MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures[.]”  On this news, Apyx’s stock price fell $4.02 per share, or 40.61%, to close at $5.88 per share on March 14, 2022.


If you are aware of any facts relating to this investigation or purchased Apyx shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.